Buparlisib
Diffuse Large B-Cell Lymphoma
Memorial Sloan Kettering Cancer CenterSmall moleculePhase 1Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 40/ 100
- Competitive Position
- 73/ 100
Competitive context
271 Active assets in the Diffuse Large B-Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINCRISTINE SULFATE National Cancer Institute (NCI) | Phase 2/3 | A |
Evomela Ruijin Hospital | Phase 4 | BBB |
Axicabtagene Ciloleucel Ruijin Hospital | Phase 4 | BBB |
PREDNISONE TABLETS Beth Israel Deaconess Medical Center | Phase 4 | BBB |
CYCLOSPORIN A Fred Hutchinson Cancer Center | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Buparlisib is also rated in:
Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular LymphomaDormant
CCC
Indicative ·
54 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →